Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Strategic Corporate Update
New York, May 15, 2026 – Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company, has released its financial results for the first quarter ended March 31, 2026, alongside a comprehensive corporate update. The company is currently undergoing a pivotal period of operational transition and strategic reassessment following recent executive management changes.
Key Points from the Report
- Executive Management Transition: Indaptus has recently undergone changes in executive leadership, resulting in a transition period marked by operational and organizational adjustments. The company is actively reviewing development programs, operational resources, and corporate initiatives.
- Strategic Review of Decoy Platform: The company is currently evaluating its Decoy platform, focusing on preclinical data and scientific rationale to determine its relevance to ongoing therapeutic, immunological, and translational research activities. This could lead to a significant shift in development priorities and resource allocation.
- Preferred Stock Conversion: All outstanding shares of Series AA and Series AAA Preferred Stock were converted into common stock during the first quarter of 2026. This simplifies the company’s capital structure and could affect future dilution and shareholder composition.
Financial Highlights for Q1 2026
- Research and Development Expenses: R&D expenses dropped significantly to \$0.5 million from \$2.8 million in Q1 2025, primarily due to \$1.9 million lower clinical costs related to the company’s Phase 1 study and a \$0.4 million reduction in payroll costs from headcount and salary cuts.
- General and Administrative Expenses: G&A expenses were \$1.7 million, down 5% from \$1.8 million in the prior year, attributable to lower public company operating expenses and management transition costs.
- Net Loss: The net loss was \$2.5 million, a notable improvement from \$4.5 million in Q1 2025. Loss per share was \$0.23 (vs. \$9.11 in Q1 2025), with all figures retroactively adjusted for a one-for-twenty-eight reverse stock split effected on June 27, 2025.
- Cash Position: Indaptus ended the quarter with \$1.5 million in cash and cash equivalents, a sharp decline from \$8.5 million as of December 31, 2025. The company acknowledged it will need to raise additional capital to meet business objectives and is currently assessing financing alternatives and strategic options.
- Cash Flow: Net cash used in operating activities was \$7.0 million (vs. \$5.0 million in Q1 2025), mainly due to a decrease in accounts payable and other current liabilities. There was no net cash provided by financing activities in Q1 2026 (vs. \$3.2 million in Q1 2025).
Operational and Strategic Developments
- Reassessment of Priorities: The company is in the midst of reassessing development priorities, operating initiatives, and resource allocation. This process is being guided by scientific validation, clinical and regulatory considerations, and financial constraints.
- Potential Strategic Transactions: Indaptus is exploring strategic options, including possible investments in or acquisitions of operating businesses, and the appointment of a scientific consultant. These developments could result in material changes to the company’s business model or pipeline focus in the near future.
- Risks and Uncertainties: Management highlighted substantial risks, including the company’s limited operating history, the need for additional capital, uncertainties arising from management transition, and the possibility of discontinuing further clinical enrollment in ongoing studies.
- Reverse Stock Split: All reported share and per-share data has been retroactively adjusted to reflect the company’s one-for-twenty-eight reverse stock split executed on June 27, 2025. This is a key structural change for investors to be aware of and could affect trading and valuation dynamics going forward.
Balance Sheet and Capital Structure
- Assets: As of March 31, 2026, Indaptus reported \$2.2 million in total current assets, down from \$9.3 million at year-end 2025.
- Liabilities: Current liabilities decreased sharply to \$0.93 million from \$6.16 million at December 31, 2025.
- Shareholders’ Equity: Total stockholders’ equity stood at \$1.25 million, down from \$3.15 million at year-end 2025. Common shares outstanding increased to 113,242,324 (post-split), reflecting the conversion of preferred stock to common stock.
Important Shareholder Considerations and Potential Price-Sensitive Factors
- Urgent Capital Needs: The company’s dwindling cash position (\$1.5 million) and explicit statement about needing to raise capital or pursue strategic alternatives is highly material and could impact share price depending on the company’s ability to secure financing or a strategic transaction.
- Ongoing Strategic Review: Indaptus’ review of development priorities, particularly regarding the Decoy platform, and openness to potential investments or acquisitions, introduces uncertainty but also the prospect of transformative change that could significantly affect valuation.
- Streamlined Capital Structure: The conversion of preferred stock to common stock and the recent reverse stock split may affect the company’s appeal to institutional investors and could influence future dilution risk.
- Reduced Operating Expenses: The sharp reduction in R&D and G&A spending reflects a major operational contraction, possibly indicative of a pause or change in clinical development plans.
- Discontinued Clinical Enrollment: The company has decided to discontinue further enrollment in the Combination Study and is not planning a new clinical trial at this time, which may affect future product development timelines and investor sentiment.
About Indaptus Therapeutics
Indaptus Therapeutics is focused on developing a novel, systemically-administered anti-cancer and anti-viral immunotherapy platform. The technology is based on attenuated, killed Gram-negative bacteria designed to safely stimulate both innate and adaptive immune responses. The company is currently reviewing its corporate direction, development priorities, and potential collaborative opportunities in light of recent operational changes.
Forward-Looking Statements
This release contains forward-looking statements regarding Indaptus’ business plans, strategic initiatives, financial condition, and product development activities. These statements are subject to significant risks and uncertainties, including the company’s need for additional capital, potential shifts in business strategy, management transition, and the uncertain outcomes of both clinical and corporate development activities.
Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors are encouraged to review the company’s filings with the Securities and Exchange Commission (SEC) and to consult with their financial advisors before making any investment decisions. All forward-looking statements in this article are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
